TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31382210
Drug: TENS (pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS (pulse of 200 μs, frequency at 10 Hz, in motor threshold) for 20 min followed by 30 min of vocal therapy
Study: 31382210
Drug: Placebo TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TENS for 20 min followed by 30 min of vocal therapy
Study: 18818443
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of donepezil (Aricept) daily for 6 weeks, increased to 10 mg daily for another 6 weeks, followed by cognitive training for 2 weeks and maintained for 1 year
Study: 18818443
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 6 weeks, followed by cognitive training for 2 weeks and maintained for 1 year
Study: 11994052
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg day-1)
Study: 11994052
Drug: Clomiphene (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (50-100 mg for 5 days) with Metformin
Study: 11994052
Drug: Clomiphene (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (50-100 mg for 5 days) with Placebo
Study: 7772427
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 15 mg kg‐1
Study: 442002
Drug: Intraderma injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderma injection of a suspension of irradiated autologous tumour-cells mixed with intradermal BCG
Study: 21860157
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% permethrin (group A)
Study: 21860157
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (200 μg/kg/dose) in a single dose (group B)
Study: 21860157
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (200 μg/kg/dose) in a double dose regimen (group C)
Study: 19462326
Drug: Flavor-enhanced tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor-enhanced tomato soup (1,200 mg/l MSG + 3 g/l celery powder)
Study: 16946093
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 100 microg LPS
Study: 10924300
Drug: Intravenous sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sotalol (1.5 mg. kg(‐1))
Study: 8644832
Drug: Activity-based therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based therapy regimen (30 min each day)
Study: 31213572
Drug: Individual inhalation
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual inhalation training (study group)
Study: 24201696
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo daily for 20 weeks
Study: 22776627
Drug: No helmet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No helmet therapy
Study: 7593436
Drug: Sandostatin-LAR (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandostatin-LAR (20, 30, or 40 mg) administered via intramuscular injections at 28- or 42-day intervals
Study: 26150412
Drug: SCAMP (30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCAMP (30% more parenteral nutrition amino acids)
Study: 26150412
Drug: Control parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control parenteral nutrition regimen
Study: 11899783
Drug: Vinorelbine in
Normalized name: vinorelbine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine in combination with trastuzumab and newer molecular targeting agents
Study: 11899783
Drug: Vinorelbine in
Normalized name: vinorelbine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine in doublets or triplets with drugs other than anthracyclines and taxanes
Study: 9272782
Drug: Morphine test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine test
Study: 9272782
Drug: Chronic motor
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic motor cortex stimulation therapy
Study: 7881144
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of bupivacaine during both S1 and S2 (Group C)
Study: 7881144
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of saline during S1 and S2 (Group A)
Study: 7881144
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of saline during S1 and 20 mL of bupivacaine during S2 (Group B)
Study: 26068297
Drug: Intermittent PTH
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intermittent PTH administration (iPTH)
Study: 23587982
Drug: Desvenlafaxine 25
Normalized name: DESVENLAFAXINE 25 mg ORAL TABLET, EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 25 mg/day (initial dose), titrated to a maximum of 100 mg/day based on clinical response
Study: 23587982
Drug: Desvenlafaxine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (various doses)
Study: 21693027
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted Problem Solving Therapy (C-MAP), 8 sessions lasting approximately 50 minutes each over 3 months
Study: 20015817
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of the catheter after discontinuation of PCEA (Group 2)
Study: 16230866
Drug: BNP-guided up-titration
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided up-titration of beta blocker
Study: 12746760
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Pioglitazone once daily
Study: 7503047
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of vitamin C and beta-carotene (mean intakes: 138 mg/day vitamin C, 5.3 mg/day beta-carotene)
Study: 24074457
Drug: Intranasal inhalation
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal inhalation of 24 IU of oxytocin
Study: 20197785
Drug: A. bisporus
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. bisporus alpha‐glucans (5 g glucans/day)
Study: 20197785
Drug: Control fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control fruit juice (200 ml/day)
Study: 17628352
Drug: Reserpine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (0.5 mg/day)
Study: 16376736
Drug: Conversations about
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversations about treatment preferences
Study: 10205584
Drug: Bedtime uncooked
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime uncooked cornstarch (0.3 g kg‐1 body weight)
Study: 10205584
Drug: Conventional snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional snack (wholemeal bread, 0.6 g of carbohydrates kg‐1 body weight)
Study: 417644
Drug: L-amino acid
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose and fructose
Study: 417644
Drug: L-amino acid
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose, fructose, and fat emulsions (30-40% of total calories, 30 kcal/kg body weight/day)
Study: 31876947
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy for chronic pain
Study: 31876947
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (taper only)
Study: 27324506
Drug: LCZ696 (sacubitril/valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (sacubitril/valsartan) 20-600 mg
Study: 27324506
Drug: LCZ696 (sacubitril/valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (sacubitril/valsartan) 200 mg with food
Study: 26688235
Drug: Methotrexate (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (3.5 g/m²) with temozolomide (150 mg/m²)
Study: 26688235
Drug: Methotrexate (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (3.5 g/m²), procarbazine (100 mg/m²), vincristine (1.4 mg/m²), and cytarabine (3 mg/m²)
Study: 23421759
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg daily for 12 months)
Study: 23421759
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose monohydrate and stearic acid, same weight as zinc capsules)
Study: 16601659
Drug: Genital ulcer
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Genital ulcer treatment in the last year
Study: 25085275
Drug: GS 500
Normalized name: acetaminophen/herbal drugs 500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS 500 mg/CS 400 mg three times daily capsules (GI)
Study: 25085275
Drug: GS 500
Normalized name: acetaminophen/herbal drugs 500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS 500 mg/CS 400 mg once daily sachet (GII)
Study: 25085275
Drug: GH 500
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 500 mg/CS 400 mg three times daily (GIII)
Study: 23588112
Drug: Growth-arrested neonatal
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth-arrested neonatal dermal fibroblasts and keratinocytes delivered via pump spray in a fibrin sealant-based matrix, plus a foam dressing and four-layer compression bandaging for 12 weeks or until healed.
Study: 23588112
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (no active treatment).
Study: 21915478
Drug: L-thyroxine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine replacement
Study: 17029610
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b (100 microg weekly for 52 weeks)
Study: 28238203
Drug: JNJ‐53718678 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐53718678 (single doses of 25-1000 mg)
Study: 28238203
Drug: JNJ‐53718678 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐53718678 (multiple doses of 250 mg every 24 h, 500 mg q24h, 250 mg every 12 h for 8 days)
Study: 20215977
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (ET) - conjugated equine estrogens 0.625 mg daily
Study: 20215977
Drug: Estrogen +
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen + progesterone therapy (EPT) - ET plus medroxyprogesterone acetate 2.5 mg daily
Study: 10445673
Drug: Levosimendan (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (18 or 36 microg/kg loading dose and 0.2 or 0.3 microg/kg/min infusion)
Study: 10445673
Drug: Levosimendan (high-dose)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (high-dose)
Study: 15025738
Drug: Levosimendan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (both doses)
Study: 316786
Drug: Portacaval shunt
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portacaval shunt surgical treatment
Study: 316786
Drug: No surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgical treatment (control)
Study: 6354422
Drug: Superfractionation (SF)
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superfractionation (SF) radiation therapy (4000 rad in 45 fractions in 3 weeks whole brain and 1000 rad in five fractions in one week local boost)
Study: 6354422
Drug: Conventional Fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Fractionation (CF) radiation therapy (3400 rad in 17 fractions whole brain in 3.5 weeks and 1600 rad in eight fractions in 1.5 weeks local boost)
Study: 6354422
Drug: Superfractionation (SF)
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superfractionation (SF) radiation therapy
Study: 31282028
Drug: Placebo (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plus standard of care therapy)
Study: 29432959
Drug: 12 SQ‐HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 SQ‐HDM (sublingual immunotherapy tablet)
Study: 24128654
Drug: Salmon consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon consumption (two 150 g portions of farmed salmon per week from 20 weeks of pregnancy to delivery)
Study: 22397774
Drug: Intrarectal gel
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal gel instillation
Study: 18629526
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg venlafaxine
Study: 11882931
Drug: r‐HuEPO+intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO+intravenous iron (EPO+IV)
Study: 11882931
Drug: r‐HuEPO+oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO+oral iron (EPO+OR)
Study: 10531077
Drug: DMARD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD and prednisolone (mean dose 6 mg, mean cumulated dose 2160 mg)
Study: 7789045
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of angiotensin-converting enzyme (lisinopril)
Study: 2112177
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 to 1.0 mg)
Study: 30327952
Drug: Brush-off patch
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brush-off patch containing 3.0% hydrogen peroxide applied for 10 min twice daily (case 10 group)
Study: 30327952
Drug: Brush-off patch
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brush-off patch containing 3.0% hydrogen peroxide applied for 30 min once daily (case 30 group)
Study: 26918556
Drug: Miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50 mg) just before breakfast (intake schedule B)
Study: 26918556
Drug: Miglitol dissolved
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol dissolved in water (50 mg) taken just before, during, and just after breakfast (intake schedule C)
Study: 21930328
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg (ACCEPT trial)
Study: 21930328
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg (ACCEPT trial)
Study: 7549411
Drug: Caffeine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.5 mg/kg in 200 ml)
Study: 7549411
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg made up to 200 ml)
Study: 26731113
Drug: Promitor™ Soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promitor™ Soluble Corn Fibre (SCF) at 6 g/fibre/day
Study: 26731113
Drug: Promitor™ Soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promitor™ Soluble Corn Fibre (SCF) at 12 g/fibre/day
Study: 26731113
Drug: Promitor™ Soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promitor™ Soluble Corn Fibre (SCF) at 18 g/fibre/day
Study: 15650986
Drug: Morphine HCl
Normalized name: morphine HCl
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine HCl (1 mg/mL) with an infusion rate of 0.3 mg/h and 1‐mg bolus doses
Study: 15650986
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 microg/mL) with an infusion rate of 1 microg/kg/h and 10‐microg bolus
Study: 15650986
Drug: Remifentanil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (50 microg/mL) with an infusion rate of 0.05 microg/kg/min and 0.5‐microg/kg bolus
Study: 8150634
Drug: Systemic venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic venous infusions (SVI) with netilmycin, three times/day for 10 days
Study: 29373242
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) cream 0.05%
Study: 27197727
Drug: Transmeatal low‐level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmeatal low‐level laser therapy for tinnitus
Study: 18312937
Drug: Intracavernosal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal saline infusion
Study: 16151336
Drug: Etanercept (ETA)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETA) 25 mg SC twice weekly for 8 weeks
Study: 10490438
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg triptorelin intramuscularly every four weeks (group 1)
Study: 8628471
Drug: Coagulant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulant or antiaggregant therapy, surgical closure of PFO
Study: 8628471
Drug: Treatment type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type (coagulant or antiaggregant therapy, surgical closure of PFO)
Study: 3524513
Drug: Clinic treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic treatment by a speech pathologist for 12 weeks, followed by 12 weeks of no treatment
Study: 3524513
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment by a trained volunteer for 12 weeks, followed by 12 weeks of no treatment
Study: 3524513
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment for 12 weeks, followed by 12 weeks of treatment by a speech pathologist
Study: 19508159
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) trivalent, inactivated influenza vaccine (60 microg of hemagglutinin per strain)
Study: 19508159
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) trivalent, inactivated influenza vaccine (15 microg of hemagglutinin per strain)
Study: 19508159
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) trivalent, inactivated influenza vaccine
Study: 16817038
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of dialysis treatment.
Study: 10688090
Drug: Placebo 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.20 g
Study: 21332937
Drug: Four-times faster
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-times faster infusion rate delivery (FIRD)
Study: 21332937
Drug: Slower infusion
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower infusion rate delivery (SIRD)
Study: 19919768
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) for asymptomatic children aged <6 years
Study: 9416380
Drug: Modified heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified heparin dosing nomogram (institution-specific)
Study: 9416380
Drug: Physician-directed dosing
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-directed dosing
Study: 9416380
Drug: Unmodified heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified heparin dosing nomogram (18 units/kg/h)
Study: 8311278
Drug: S (+)
Normalized name: Guardian Paracetamol Extra Plus (+) (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S (+) ketamine (1 mg/kg, Group I, n = 30)
Study: 8311278
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine (2 mg/kg, Group II, n = 30)
Study: 28453453
Drug: Magnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic therapy for 50 minutes per session, two sessions per week for 4 months
Study: 28453453
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment alone (control group)
Study: 23182407
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg pramipexole
Study: 18458518
Drug: Integrated symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated symptom management program for 6 months (tailored education, stress management, exercise, diet, deep breathing, music therapy, periodical telephone monitoring, daily log)
Study: 16569351
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin (15 mg aerosolized, twice daily for 10 days)
Study: 16569351
Drug: Oral amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/clavulanate (50 mg/Kg, twice daily for 10 days)
Study: 1395889
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of aminophylline slowly
Study: 1395889
Drug: Traditional three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional three drugs combination treatment
Study: 24905629
Drug: Ephedrine/caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine/caffeine combination (200/20 mg, n=6)
Study: 22301417
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) twice daily after a 14-day once-daily lead-in period
Study: 17106838
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital detoxification treatment
Study: 10086941
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 microg or one puff twice daily)